Inotropes are medications that change the force of your heart’s contractions. Positive inotropes make the heart squeeze harder, while negative inotropes reduce the force of each beat. They’re most commonly used in hospital settings when the heart isn’t pumping effectively enough to deliver blood to the body’s organs, a situation that occurs in about 10% of all heart failure hospitalizations.
How Inotropes Work
Every heartbeat involves a carefully orchestrated flow of calcium into heart muscle cells. The more calcium that enters, the stronger the contraction. Positive inotropes exploit this system in different ways, but they all ultimately increase the amount of calcium available inside heart muscle cells, which makes each squeeze more powerful. This raises cardiac output, meaning more blood reaches the brain, kidneys, and other organs with each beat.
Negative inotropes do the opposite. By reducing calcium availability or blocking the signals that drive forceful contractions, they dial down how hard the heart works. This lowers the heart’s oxygen demand, which is useful in conditions like high blood pressure, chest pain from coronary artery disease, or certain abnormal heart rhythms.
Positive Inotropes
Positive inotropes are the type most people encounter in medical conversations. They fall into a few major groups based on how they boost the heart’s pumping strength.
Catecholamines
These drugs mimic or amplify the body’s natural “fight or flight” chemicals. Dobutamine is one of the most widely used. It primarily stimulates receptors on heart muscle cells that ramp up contraction force, with mild blood vessel relaxation at lower doses. Dopamine, epinephrine, and norepinephrine also fall into this category. Each has a slightly different balance of effects on the heart versus the blood vessels, which is why doctors choose specific agents based on a patient’s blood pressure and underlying condition.
PDE3 Inhibitors (Inodilators)
Milrinone is the best-known drug in this class. Rather than stimulating the same receptors as catecholamines, it blocks an enzyme that breaks down a signaling molecule inside heart cells. The result is stronger contractions plus significant relaxation of blood vessels. Because milrinone doesn’t work through the same pathway as catecholamines, it carries a lower risk of racing heart rates. The tradeoff is that it tends to cause more blood pressure drops, often requiring an additional medication to keep pressure stable. These drugs are particularly useful for patients who have constricted blood vessels or elevated pressure in the lungs.
Digoxin
Digoxin stands apart from other positive inotropes because it’s taken as a pill rather than given through an IV. It works by blocking a pump on heart cell membranes that normally moves sodium and potassium in and out of cells. When that pump is inhibited, sodium builds up inside the cell, which indirectly causes more calcium to stay inside, strengthening contractions. Digoxin has been used for decades, but it has a narrow margin between a helpful dose and a toxic one. It’s now reserved mostly for mild to moderate heart failure when other treatments aren’t enough, or as a backup option for controlling heart rate.
Levosimendan
Available in Europe but not the United States, levosimendan works by making heart muscle cells more sensitive to the calcium already present rather than increasing calcium levels. It also relaxes blood vessels. European guidelines suggest it for heart failure patients whose low blood flow may be related to beta-blocker therapy, since it works through an entirely different pathway.
Negative Inotropes
Negative inotropes are prescribed far more commonly than positive ones, though people rarely think of them in those terms. Beta-blockers and certain calcium channel blockers both reduce contractile force, but that’s often a feature rather than a side effect.
Beta-blockers slow the heart rate and reduce how hard it squeezes. This lowers the heart’s oxygen consumption, which is why they’re a cornerstone treatment for high blood pressure, coronary artery disease, and certain arrhythmias. By easing the heart’s workload, they also help in long-term management of heart failure, despite seeming counterintuitive.
Calcium channel blockers like verapamil and diltiazem directly limit how much calcium enters heart muscle cells, reducing contraction strength. They’re used for high blood pressure, chest pain, and some rhythm disturbances. Other negative inotropes include certain antiarrhythmic drugs like procainamide and flecainide, which are prescribed specifically to correct irregular heart rhythms.
When Positive Inotropes Are Used
Positive inotropes are indicated when the heart can’t pump enough blood to keep organs functioning. This manifests in two broad scenarios. The first is cardiogenic shock, where blood pressure drops dangerously low (typically below 85 mmHg) because the heart is failing as a pump. The second is less dramatic but still serious: heart failure patients whose blood pressure may be borderline or even normal, but whose organs still aren’t getting adequate blood flow. Signs of this poor perfusion include cool extremities, decreased urine output, confusion, and worsening kidney function.
The specific choice of inotrope depends on what else is going on. A patient whose heart failure stems from sepsis typically receives different agents than someone recovering from cardiac surgery or dealing with high pressure in the lung arteries. Coexisting conditions like kidney dysfunction, low blood pressure, or ongoing beta-blocker therapy all influence which drug is most appropriate.
How They’re Given and Monitored
Most positive inotropes (except digoxin) are delivered as continuous IV drips, with the dose adjusted in real time based on how the patient responds. This almost always happens in an intensive care unit or a step-down unit with close monitoring capabilities. Patients typically have a continuous blood pressure reading from an arterial line, a small catheter placed directly in an artery rather than relying on a standard blood pressure cuff. Heart rhythm is tracked continuously on a monitor.
The goal is to use inotropes for the shortest effective period. They serve as a bridge to stabilize someone while the underlying cause is treated, or while decisions are made about longer-term options like surgery or a mechanical heart pump. Prolonged use is avoided when possible because of the associated risks.
Risks and Side Effects
The major concern with positive inotropes is that while they improve the heart’s pumping in the short term, they can increase the risk of dangerous heart rhythm disturbances. This applies across the board, from dobutamine to milrinone to epinephrine, though the severity varies by drug and dose.
Dobutamine can trigger arrhythmias at most doses and has been linked to higher rates of in-hospital mortality and future heart failure readmissions in some analyses. Epinephrine carries the highest risk profile of the catecholamines: it has been independently associated with increased 90-day mortality in cardiogenic shock and can cause lactic acidosis, reduced blood flow to the gut, and worsening kidney and heart function. Milrinone, despite its gentler effect on heart rate, causes prolonged drops in blood pressure and has been tied to higher death rates in patients whose heart failure stems from blocked coronary arteries.
Even levosimendan, often positioned as a gentler alternative, failed to reduce mortality in one major randomized trial and caused more cases of arrhythmias and low blood pressure than placebo. All positive inotropes share an unfavorable impact on long-term survival, which is why their use is restricted to situations where the immediate benefit of restoring blood flow to vital organs outweighs these risks. They are rescue medications, not maintenance therapy.
Negative inotropes carry their own risks, primarily excessive slowing of the heart or dangerously low blood pressure, but these are generally more predictable and manageable with dose adjustments.